Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury
Launched by LIMENG CHEN · Jul 15, 2018
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
The incidence of acute kidney injury (AKI) is rapidly increasing worldwide. This is a common and devastating disorder, especially in critical illnesses, affecting 5-8% of all hospitalized patients and up to 30% of those in intensive care units, with high mortality. About 50-80% critical patients with AKI needed dialysis treatment. Intermittent hemodialysis (IHD) might be the most-commonly modalities applied in AKI patients requiring dialysis. However, no data of randomized study concerning renal recovery and treatment efficiency of AKI patients treated with APD is available in Chinese adult...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • AKI patients according to Acute Kidney Injury Network criteria
- • Rapidly rising serum creatinine level (a sudden increase of at least 30%)
- • Meeting the indications for dialysis
- • Uremia or azotemia (BUN\>80 mg/dl)
- • Fluid overload (after diuretics use)
- • Electrolyte imbalance (K\>5.5 mEq/L after clinical treatment)
- • Acid-base disturbance (pH\<7.2 and bicarbonate\<10mEq/L after clinical treatment)
- Exclusion Criteria:
- • Age under 18 years, or older than 80 years
- • Urinary tract obstruction; acute interstitial nephritis or rapidly progressive glomerulonephritis needed immunoinhibitory therapy
- • Previously received renal replacement therapy(RRT) of any type/presence of dialysis access during the current illness.
- • Pre-existing severe chronic kidney disease (baseline serum creatinine\>4mg/dl) more than 10 days prior to initiation of first RRT.
- • Absolute contraindication of peritoneal dialysis such as recent abdominal surgery (\<1month), multiple abdominal surgeries.
- • Absolute contraindication for hemodialysis such as hemodynamic instability (systolic blood pressure \<80mmHg).
- • Pregnant.
About Limeng Chen
Limeng Chen is a dedicated clinical trial sponsor specializing in the design, implementation, and management of innovative clinical research studies. With a strong focus on advancing medical knowledge and improving patient outcomes, Limeng Chen collaborates with leading healthcare institutions and research organizations to conduct trials across various therapeutic areas. Committed to maintaining the highest standards of ethical practice and regulatory compliance, the sponsor leverages cutting-edge methodologies and technologies to ensure rigorous data collection and analysis. Through these efforts, Limeng Chen aims to contribute significantly to the development of new treatments and therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Shenyang, Liaoning, China
Changsha, , China
Changsha, Hunan, China
Xi'an, Shanxi, China
Beijing, Beijing, China
Xi'an, Shannxi, China
Patients applied
Trial Officials
Limeng Chen, MD, PhD
Principal Investigator
Division of Nephrology, Peking Union Medical College Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials